CD38 and inflammaging CD38, a NAD+-consuming enzyme, becomes more active with age and chronic inflammation
The SELECT trial, published in the New England Journal of Medicine in 2023, showed that semaglutide reduced major adverse cardiovascular events by 20% in patients with obesity and established cardiovascular disease
We used ddPCR Supermix for probes (Bio-Rad product number 186-3010), an automated droplet generator and droplet reader (Bio-Rad QX200), and PCR cycling conditions according to the manufacturers instructions as follows: enzyme activation 95 C for 10 min (one cycle), denaturation 94 C for 30 s followed by annealing/extension at 60 C for 1 min (40 cycles), enzyme deactivation 98 C for 10 min (one cycle), and hold at 4 C, as previously described 19
Glucagon-like peptide-1 receptor agonists and risk for gastroesophageal reflux disease in patients with type 2 diabetes: a population-based cohort study
Peptide Evidence, Safety and Regulation in Canada Peptides in Canada: approved medicines, research chemicals, marketing and safety